Previous 10 | Next 10 |
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO PR Newswire - Extended follow-up in the Actimab-A + CLAG-M trial showed median overall sur...
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting PR Newswire - First ever data demonstrating anti-leukemic effect of Actimab-A in FLT3 Mutant AML models NEW YORK , Aug. 31, 2023 /PRNewswire/ --...
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress PR Newswire NEW YORK , Aug. 21, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the developm...
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit PR Newswire NEW YORK , July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted rad...
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data PR Newswire - SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK ...
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting PR Newswire NEW YORK , June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in th...
Actinium Pharma to Present at the Maxim Healthcare Virtual Conference PR Newswire NEW YORK , June 16, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, toda...
Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit PR Newswire NEW YORK , June 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted...
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress PR Newswire SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by y...
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes PR Newswire NEW YORK , June 7, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, t...
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
2024-05-16 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity PR Newswire - KOL and principal investigator, Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at Univer...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial PR Newswire ...